Inventiva Appoints Chris Benecchi as Chief Operating Officer

Phase 3lanifibranorPositive

AI Analysis

Summary

Inventiva appointed Chris Benecchi as Chief Operating Officer to lead operational readiness ahead of lanifibranor's Phase 3 NATiV3 topline results expected in Q4 2026 for MASH treatment.

Clinical Trial Data

Phase

Phase 3

Outcome Details

NATiV3 Phase 3 topline study results expected

Importance:4/10

Sentiment:

0.30

managementPhase 3MASHoperational readinesscommercialization

Related Companies

$IVA

Read the original article

Published by GlobeNewswire Pharma on August 31, 2026 8:05 PM

Read Original